Oncology
1 drug is in development for Ovarian Neoplasms.
- Companies
- 1
- Clinical trials
- 17
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Ovarian Neoplasms pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| tc-510 | TCR2 THERAPEUTICS INC. (TCRR) |
About this indication
Ovarian Neoplasms context
Oncology·MeSH: Ovarian Neoplasms (D010051)
Also known as: Neoplasm, Ovarian, Neoplasm, Ovary, Neoplasms, Ovary
Narrower concepts tracked separately: Ovarian Cancer, Ovary Cancer
Prevalence
24.0 / 100K
Incidence
10.6 / 100K/yr
Frequently asked questions
How many drugs are in development for Ovarian Neoplasms?
BioSniper tracks 1 drug in development for Ovarian Neoplasms across 1 company.
How many clinical trials target Ovarian Neoplasms?
There are 17 clinical trials targeting Ovarian Neoplasms tracked by BioSniper.
What is the prevalence of Ovarian Neoplasms?
The estimated prevalence of Ovarian Neoplasms is approximately 24.0 per 100,000 population.